Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–116 of 116 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Glaxo Wellcome Clear all

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 5
States / cities: Palo Alto, California • Washington D.C., District of Columbia • Pittsburgh, Pennsylvania + 1 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 44
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more

Conditions: HIV Infections
Interventions: Hydroxyurea, Abacavir sulfate, Efavirenz, Didanosine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 23
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 19 more

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Abacavir sulfate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Los Angeles, California • Oakland, California • Washington D.C., District of Columbia + 16 more

Conditions: HIV Infections
Interventions: Methadone hydrochloride, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections, Lipodystrophy
Interventions: Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 31
States / cities: Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 20 more

Conditions: HIV Infections
Interventions: Alvircept sudotox, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 4
States / cities: Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 1 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Amprenavir, Efavirenz, Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 13
States / cities: San Francisco, California • Indianapolis, Indiana • New Orleans, Louisiana + 7 more

Conditions: HIV Infections
Interventions: Interferon alfa-2a, Zidovudine, Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 4
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 1 more

Conditions: HIV Infections
Interventions: Ranitidine hydrochloride; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Sherman Oaks, California • Coral Gables, Florida • Durham, North Carolina + 1 more

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Maribavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 35
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 22 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone, Pentamidine isethionate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 20
States / cities: Berkeley, California • Harbor City, California • Los Angeles, California + 12 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: HIV Infections
Interventions: Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Lamivudine, Stavudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: Abacavir sulfate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Diego, California • San Francisco, California • Baltimore, Maryland + 3 more

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine, Interferon alfa-n1; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: San Francisco, California • San Rafael, California • Washington D.C., District of Columbia + 10 more

Conditions: HIV Infections
Interventions: Amprenavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Memphis, Tennessee

Search by objective public record fields.

A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease

An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine

Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

The Effect of Teaching HIV-Infected Patients About HIV and Treatment

Methadone Effects on Zidovudine (ZDV, AZT) Disposition

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons

Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex

A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3

A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients

A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past

A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole

An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection

Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors